’EXO-CD24 is an experimental “precision” medication for inhalation, developed by Professor Nadir Arber at Tel Aviv Sourasky Medical Center.Its aim is to halt the “cytokine storm” that affects the lungs of approximately 5-7 per cent of covid-affected patients. This occurs when the immune system starts attacking healthy cells with extra cytokine cells’
Great work from NOX but there is a lot happening in this space (COVID). Read this one today and I hope they’re still going hard on the oncology side. I’d go an inhaler over a suppository given a choice.
https://www.news.com.au/world/coronavirus/health/israel-claims-new-covid-treatments-could-be-a-gamechanger/news-story/24dc5b247c9a8d149427fcb568429799
Ann: NOXCOVID Program to Expand After Positive Phase 1 Results, page-21
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |